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Abstract
Background: Pathologists are often faced with the dilemma of whether to recommend
continuation of methotrexate therapy for psoriasis within the context of an existing pro-fibrogenic
risk factor, in this instance, patients with genetic hemochromatosis.
Case presentations: We describe our experience with two male psoriatic patients (A and B) on
long term methotrexate therapy (cumulative dose A = 1.56 gms and B = 7.88 gms) with hetero-
(A) and homozygous (B) genetic hemochromatosis. These patients liver function were monitored
with routine biochemical profiling; apart from mild perivenular fibrosis in one patient (B), significant
liver fibrosis was not identified in either patient with multiple interval percutaneous liver biopsies;
in the latter instance this patient (B) had an additional risk factor of partiality to alcohol.
Conclusion: We conclude that methotrexate therapy is relatively safe in patients with genetic
hemochromatosis, with no other risk factor, but caution that the risk of fibrosis be monitored,
preferably by non-invasive techniques, or by liver biopsy.
Background
Liver fibrosis, increased liver collagen content, [1-3] dam-
age to the canals of Hering, [4] and cirrhosis, have been
reported in patients being treated with methotrexate for
psoriasis [5] or rheumatoid arthritis [6] but not in the con-
text of inflammatory bowel disease;[7,8] some studies
suggest that this risk of liver fibrosis is overstated [9-11].
The duration of methotrexate therapy,[12] patient age,
weekly oral dosage schedule,[13] cumulative methotrex-
ate dose,[14] risk factors for non-alcoholic steatohepatitis
(obesity, diabetes mellitus, glucose intolerance)[6,15-17]
and concurrent alcohol ingestion [14,18] have been iden-
tified as significant risk factors in the evolution of liver
fibrosis in these patients. By contrast long-term low-dose
methotrexate therapy, in the absence of excess alcohol
ingestion or other profibrogenic agents or diseases, have
been reported as being relatively free of the risk of devel-
oping fibrosis [19,20]. It has been recommended that
baseline pre-treatment liver biopsies are necessary to
define the initial histologic status of the liver [21,22].
Although annual, or other suitable interval, liver biopsies
are recommended with this treatment, to monitor devel-
opment of liver fibrosis,[12,13,17,21] its necessity in the
first five years of treatment[12] or the need at all for this
invasive procedure [11] has been questioned; recent
guidelines from the British Society of Gastroenterology do
not include methotrexate as an indication for liver biopsy
[23]. Ultrasound liver examination [24] and measure-
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INP) [25-27] have been suggested as alternatives to liver
biopsy; the former is useful only if the US appearances are
normal as it is not discriminatory in identifying fibrosis
[24]. We reflect on our experience with two patients
receiving methotrexate for psoriasis, with genetic hemo-
chromatosis (GH) as an "additional" risk factor for the
development of liver fibrosis.
Case presentations
The clinical histories of two patients (patient A and
patient B) with psoriasis, being treated with methotrexate,
are summarised. During the course of their treatment,
liver biopsies were performed as baseline to rule out and
subsequently monitor the development of liver fibrosis
as, at the present time PIIINP monitoring of liver fibrois is
not available in our institution. The possibility of GH was
queried on histological grounds and subsequently con-
firmed with genotyping.
Patient A
A 47 year-old male patient presented to the dermatologist
October 1998 following an episode of severe flare up of
psoriasis, which he had had for 15 years. His condition
improved with coal tar, hydrocortisone ointment and
UVB. However, after stopping UVB, his flare up recurred.
Methotrexate was introduced to his treatment regime.
After a satisfactory baseline blood test and a trial dose of
2.5 mg, he started methotrexate (10 mg/week) in April
1999. Two weeks later the dose was increased to 15 mg/
week. In June 1999, the dose was increased to 17.5 mg/
week and then back to 15 mg/week in July 1999 with
Perl's Prussian Blue stain for iron shows a typical pattern of iron accumulation seen in heterozygous GH (Patient A) (×20)Figure 1
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excess alcohol ingestion.
He had his first liver biopsy, six months later (October
1999) which showed moderate acinar zone 3 and 2 mac-
rovesicular steatosis, with lesser amounts of microvesicu-
lar steatosis. Acinar zone 1, grade 1 parenchymal iron
accumulation, with an acinar gradient, suggestive of het-
erozygous form of GH was seen with Perl's Prussian Blue
(figure 1); iron was not detected in sinusoidal Kupffer
cells or macrophages. There was no evidence of fibrosis or,
accumulation of copper or alpha 1 anti-trypsin. Geno-
typic studies confirmed heterozygosity for the HFE gene
mutation H63D (in the absence of C282Y).
He had his second liver biopsy in November 2001; total
cumulative methotrexate dose of 1.56 gm from his first
liver biopsy. The biopsy showed moderate macrovesicular
steatosis, mild steatohepatitis, grade 1 iron accumulation
similar to his first biopsy but no fibrosis or contra-indica-
tion to the continued use of methotrexate.
Patient B
This 58 year-old patient was first seen by the dermatolo-
gist in October 1992 with psoriasis. He responded well
with UVL and Alphosyl HC. In February 1993, his psoria-
sis got worse and methotrexate was started with a test dose
of 5mg. Following satisfactory baseline blood tests, that
was gradually increased to 30 mg/week. His skin condi-
tion improved significantly with treatment.
Grade 3 hepatocyte iron accumulation with an acinar distribution pattern consistent with homozygous GH (Patient B) (Perl's Prussian Blue: ×10)Figure 2
Grade 3 hepatocyte iron accumulation with an acinar distribution pattern consistent with homozygous GH (Patient B) (Perl's 
Prussian Blue: ×10).Page 3 of 6
(page number not for citation purposes)
BMC Dermatology 2005, 5:12 http://www.biomedcentral.com/1471-5945/5/12He stopped methotrexate before Christmas 1994 but sub-
sequently he restarted it in March 1995. He had a liver
biopsy in August 1995 (cumulative methotrexate dose of
2115 mg) which showed moderate steatosis, moderate
deposition of hemosiderin within hepatocytes and no evi-
dence of fibrosis. His liver function tests and full blood
counts were normal at that time.
He was lost for follow up for 2 years between May 1996 to
May 1998. When he was seen again in May 1998 he had
slowly rising ALT and was still on methotrexate. Another
liver biopsy (cumulative methotrexate dose of 5000 mg)
was performed which showed moderate to severe mac-
rovesicular steatosis with smaller amounts of microvesic-
ular steatosis, predominantly in acinar zones 3 and 2.
Grade 3 parenchymal iron accumulation, with an acinar
gradient, was seen in acinar zone 1 (Figure 2) suggestive
of homozygous GH. There was no evidence of fibrosis and
thus no contra-indication for continued use of methotrex-
ate. Genotypic studies confirmed homozygosity for HFE
gene mutation C282Y, following which regular venesec-
tion was arranged. He continued on methotrexate until
March 1999 when his ALT was raised at 96. However, as
stopping methotrexate did not improve his liver function
test result it was restarted together with UVL therapy in
May 1999 for flare up.
He continued with methotrexate despite failed attempt to
reduce the dose. He had another liver biopsy in October
2001 (total cumulative methotrexate dose of 7880 mg)
which showed moderate steatosis, moderate to severe
steatohepatitis, marginal perivenular fibrosis but no resid-
Following venesection (Patient B), there is no histological evidence of residual iron (×20)igure 3
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of alcohol-induced liver damage (Figure 4). As there was
no significant fibrosis, continued methotrexate adminis-
tration was not contra-indicated although he was advised
to curtail his alcohol ingestion.
Discussion
Pathologists are occasionally faced with a decision of
whether to recommend continuation of methotrexate
therapy when a patient has an "additional" risk factor for
the development of liver fibrosis and/or cirrhosis; in this
instance with two patients on long-term methotrexate
therapy who had GH. As far as we are aware, there have
been no reports in the english literature that addresses this
specific issue.
Patients with GH are at risk of developing liver fibrosis
and, in the long term, liver cirrhosis; [28-30] there is a
also, a risk of developing fibrosis with methotrexate ther-
apy alone [31,32]. Cessation of methotrexate therapy is
advised in the presence of significant liver fibrosis [13].
We have described our experience of two hemochroma-
totic patients on low dose on methotrexate therapy for rel-
atively short periods of three and five years and relatively
low cumulative doses. Although one of these patients
with homozygous GH was also partial to alcohol, he did
not show evidence of significant fibrosis apart from equiv-
ocal alcohol-associated perivenular fibrosis. In such
instances, adequate counselling of the patient of the risk
of excess alcohol in this setting is probably appropriate.
There was no evidence of liver damage or fibrosis in our
patient with heterozygous GH.
Although measurement of PIIINP can be useful in defin-
ing the development of liver fibrosis,[25] elevated or ris-
ing levels are not specific or sensitive for liver fibrosis; [25-
27] however, liver biopsy has been recommended in
patients whose PIINP levels increase from normal whilst
they are being monitored for liver fibrosis [27]. Clearly
PIIINP measurements will not distinguish fibrosis due to
methotrexate or GH, in combination or alone or, fibrosis
developing as a result of any other profibrogenic agent.
We are unable to offer PIIINP measurements for evaluat-
ing liver fibrosis in our institution.
Conclusion
We conclude that methotrexate therapy is relatively safe in
patients with GH but caution that the risk of fibrosis be
monitored, preferably by non-invasive techniques, or by
liver biopsy. We recommend that patients in this setting
be advised of the potential for liver damage especially
with "additonal" risk factors.
List of abbreviations
serum type III procollagen aminopeptide (PIIINP)
genetic hemochromatosis (GH)
ultraviolet B (UVB)
HFE: gene symbol
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